This episode examines four regulatory and operational developments shaping clinical AI deployment. We cover FDA’s announcement exempting low-risk wellness devices from premarket review, Utah’s first-in-nation AI prescription renewal program operating without physician oversight, Ceribell’s breakthrough designation for in-hospital stroke detection using EEG-based algorithms, and expanded clearance for AI-guided echocardiography extending to novice providers. The briefing also reviews Vi’s operational data from one hundred ninety million patient interactions, documenting efficiency gains in scheduling, documentation, and workflow automation across healthcare, biopharma, and wellness sectors. These developments illustrate how regulatory frameworks are adapting to AI execution layers while clinical decision authority shifts across different provider skill levels and care settings.
